Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Market Closed - Nasdaq Other stock markets 02:30:00 06/12/2025 am IST			5-day change	1st Jan Change
155.51 ^USD	+0.84%		+2.20%	+13.93%

05/12	Neurocrine Biosciences Insider Sold Shares Worth $2,289,083, According to a Recent SEC Filing	MT
03/12	Neurocrine Biosciences Insider Sold Shares Worth $905,881, According to a Recent SEC Filing	MT

Transcript : Neurocrine Biosciences, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 01

Published on 09/03/2025 at 11:35 pm IST - Modified on 09/04/2025 at 12:35 am IST

S&P Capital IQ

Presenter Speech
Joshua Schimmer (Analysts)

Now we're ready to get started. All right. Welcome, everyone. I'm Josh Schimmer from the Cantor biotech equity research team. Pleased to introduce the

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Neurocrine Biosciences, Inc.

05/12	Neurocrine Biosciences Insider Sold Shares Worth $2,289,083, According to a Recent SEC Filing	MT
03/12	Neurocrine Biosciences Insider Sold Shares Worth $905,881, According to a Recent SEC Filing	MT
02/12	Neurocrine Biosciences, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 09:30 AM
01/12	Deutsche Bank Raises Price Target on Neurocrine Biosciences to $152 From $142, Keeps Hold Rating	MT
27/11	Neurocrine Biosciences Insider Sold Shares Worth $2,150,513, According to a Recent SEC Filing	MT
25/11	Neurocrine's collaboration for pipeline and market expansion
20/11	Neurocrine Biosciences announces publication of landmark narrative review on FDA-approved VMAT2 inhibitors demonstrating unique profile of Ingrezza (valbenazine) capsules	RE
20/11	Neurocrine Biosciences, Inc. Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors	CI
18/11	Neurocrine Biosciences, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 12:00 PM
11/11	Morgan Stanley Trims Price Target on Neurocrine Biosciences to $173 From $178, Keeps Overweight Rating	MT
11/11	Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study	MT
11/11	Neurocrine Biosciences, Inc. Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder	CI
03/11	TransThera Sciences Sells NLRP3 Inhibitor License to Neurocrine Bioscience	MT
03/11	TransThera Sciences, Inc. Announces Collaboration with Neurocrine	CI
29/10	Wedbush Raises Price Target on Neurocrine Biosciences to $149 From $143, Keeps Outperform Rating	MT
29/10	Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $142 From $140, Maintains Hold Rating	MT
29/10	RBC Raises Price Target on Neurocrine Biosciences to $160 From $156, Keeps Outperform Rating	MT
29/10	Morgan Stanley Raises Price Target on Neurocrine Biosciences to $178 From $168, Keeps Overweight Rating	MT
29/10	Neurocrine Biosciences, Inc., Q3 2025 Earnings Call, Oct 28, 2025
29/10	Neurocrine Biosciences Q3 Adjusted Earnings, Revenue Rise	MT
29/10	Neurocrine Biosciences reports 28% jump in Q3 net sales, EPS beats estimates	RE
29/10	Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q3 Revenue $794.9M, vs. FactSet Est of $746.8M	MT
29/10	Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q3 Adjusted EPS $2.17 per Share, vs. FactSet Est of $2.07	MT
29/10	Tranche Update on Neurocrine Biosciences, Inc.'s Equity Buyback Plan announced on February 21, 2025.	CI
29/10	Neurocrine Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI